Catalent Pharma Solutions, a US-based provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has acquired Australian pharmaceutical packaging business, Pharmapak Technologies, for an undisclosed amount.
With this acquisition, Catalent will be able to improve its regional packaging capabilities while Pharmapak will complement Catalent's existing facility in Braeside, Victoria which produces oral dose products like softgels, Vegicaps capsules, and OptiShell capsules that are supplied throughout Asia Pacific.
The company will continue to operate as Pharmapak Technologies and retain all its 100 employees including the leadership team at its existing facility in New South Wales.
Catalent Asia Pacific president Mark Bisset said: "This acquisition complements our industry-leading oral dosage form development and manufacturing capabilities with a broader range of packaging options, from bulk supply to finished packs.
"Catalent has made substantial recent investments in Asia Pacific with a new facility in China, and last year we celebrated our 40th year in Japan with a new laboratory and the build-out of more manufacturing capacity. This latest investment is in response to strong, local market demand for both pharmaceutical, over-the-counter (OTC) and Complementary Medicine products."
Pharmapak specialises in producing primary and secondary packaging for oral pharmaceutical dose forms like blisters, bottles and a range of tertiary packaging services.
Employing around 8,500 people across 30 facilities, Catalent recorded annual revenue of more than $1.8bn in 2014. With a team of close to 1,000 scientists, the company claims to support 40% of recent new drug approvals with its different global sites producing or packaging around 100 billion units annually.
